AC
IRWD icon

Ascend Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Ascend Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-117,167
Closed -$1.02M – 163
2015
Q3 		$1.02M Buy
+117,167
New +$1.09M 0.04% 113

Other funds holding IRWD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMC
Rubric Capital Management (Connecticut) Stamford, Connecticut $6.44M AUM 43.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Ascend Capital's IRWD Position: Q4 2015 in Review

Ascend Capital sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2015, closing a stake of 117,167 shares — an estimated $1.02M sold.

Ascend Capital first reported a position in IRWD in Q3 2015 and held it in 1 quarter. The position peaked at $1.02M in Q3 2015. 137 funds tracked by Wall St. Rank hold IRWD as of Q4 2015.

  • Ascend Capital reported no remaining Ironwood Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Ascend Capital sold 117,167 Ironwood Pharmaceuticals shares in Q4 2015, an estimated $1.02M.
  • Ascend Capital first reported a position in Ironwood Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Ascend Capital's Ironwood Pharmaceuticals position peaked at $1.02M in Q3 2015.
  • 137 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2015.

Based on Ascend Capital's 13F filing for Q4 2015, filed 12 Feb 2016.